$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000165731221000037 Filed on November 09, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$0.00	$40.00M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit		$40.00M
YoY Change
Gross Profit Margin		100.0%
Selling, General & Admin	$5.757M	$10.88M	$10.92M
YoY Change	-14.46%	-0.34%	265.22%
% of Gross Profit		27.21%
Research & Development	$22.71M	$22.56M	$12.82M
YoY Change	162.53%	75.98%	-29.44%
% of Gross Profit		56.4%
Depreciation & Amortization	$162.0K	$162.0K	$350.0K
YoY Change	440.0%	-53.71%	-22.22%
% of Gross Profit		0.41%
Operating Expenses	$28.47M	$33.44M	$21.10M
YoY Change	85.08%	58.47%	-0.22%
Operating Profit		$6.557M	-$21.10M
YoY Change		-131.07%
Interest Expense	-$21.00K	$86.00K	$0.00
YoY Change	-105.12%		-100.0%
% of Operating Profit		1.31%
Other Income/Expense, Net	$4.975M	$4.621M	$2.217M
YoY Change	-50.25%	108.43%	-4534.0%
Pretax Income	-$23.51M	$11.18M	-$18.89M
YoY Change	373.08%	-159.18%	-2.39%
Income Tax	-$250.0K	$127.0K	$44.00K
% Of Pretax Income		1.14%
Net Earnings	-$23.26M	$11.05M	-$18.93M
YoY Change	88.2%	-158.38%	23.09%
Net Earnings / Revenue		27.63%
Basic Earnings Per Share		$0.02	-$0.05
Diluted Earnings Per Share	-$48.54K	$0.02	-$0.05
COMMON SHARES
Basic Shares Outstanding	480.1M shares	475.3M shares	344.8M shares
Diluted Shares Outstanding		515.8M shares	344.8M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$148.4M	$166.5M	$260.9M
YoY Change	-21.07%	-36.16%	416.63%
Cash & Equivalents	$148.4M	$166.5M	$202.0M
Short-Term Investments			$0.00
Other Short-Term Assets	$2.063M	$667.0K	$6.000M
YoY Change	19.94%	-88.88%	39.53%
Inventory
Prepaid Expenses	$4.037M	$6.672M
Receivables
Other Receivables
Total Short-Term Assets	$170.1M	$184.5M	$274.4M
YoY Change	-16.02%	-32.77%	340.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.00K	$88.00K	$1.700M
YoY Change	-25.23%	-94.82%	21.43%
Goodwill	$545.0K	$545.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$16.52M	$17.07M	$43.10M
YoY Change	870.86%	-60.4%	817.02%
TOTAL ASSETS
Total Short-Term Assets	$170.1M	$184.5M	$274.4M
Total Long-Term Assets	$16.52M	$17.07M	$43.10M
Total Assets	$186.6M	$201.6M	$317.5M
YoY Change	-8.63%	-36.52%	373.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.04M	$9.000K	$18.30M
YoY Change	5542.7%	-99.95%	27.97%
Accrued Expenses	$22.26M	$26.46M
YoY Change	104.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$1.000M
YoY Change			100.0%
Total Short-Term Liabilities	$33.42M	$27.74M	$21.80M
YoY Change	135.32%	27.25%	42.48%
LONG-TERM LIABILITIES
Long-Term Debt	$4.874M	$4.800M	$900.0K
YoY Change	5.16%	433.33%	12.5%
Other Long-Term Liabilities	$286.0K	$797.0K	$39.50M
YoY Change	-42.8%	-97.98%	2721.43%
Total Long-Term Liabilities	$5.160M	$5.618M	$40.40M
YoY Change	0.21%	-86.09%	1736.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.42M	$27.74M	$21.80M
Total Long-Term Liabilities	$5.160M	$5.618M	$40.40M
Total Liabilities	$38.58M	$33.36M	$62.10M
YoY Change	99.37%	-46.28%	254.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$263.7M	-$240.3M
YoY Change	27.37%
Common Stock	$31.86M	$31.86M
YoY Change	0.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$603.0K	$770.0K
YoY Change	-64.53%
Treasury Stock Shares
Shareholders Equity	$148.0M	$168.2M	$196.8M
YoY Change
Total Liabilities & Shareholders Equity	$186.6M	$201.6M	$317.5M
YoY Change	-8.63%	-36.52%	373.88%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$23.26M	$11.05M	-$18.93M
YoY Change	88.2%	-158.38%	23.09%
Depreciation, Depletion And Amortization	$162.0K	$162.0K	$350.0K
YoY Change	440.0%	-53.71%	-22.22%
Cash From Operating Activities	-$17.32M	$22.83M	-$16.63M
YoY Change	39.25%	-237.25%	-46.73%
INVESTING ACTIVITIES
Capital Expenditures	-$1.000K	-$11.00K	-$240.0K
YoY Change	-100.33%	-95.42%	-7.69%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$2.620M
YoY Change	-100.0%	-100.0%	-94.68%
Cash From Investing Activities	-$1.000K	-$11.00K	$2.370M
YoY Change	-99.96%	-100.46%	-95.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-901.0K	-1.817M	238.9M
YoY Change	-98.05%	-100.76%	-62963.16%
NET CHANGE
Cash From Operating Activities	-17.32M	22.83M	-16.63M
Cash From Investing Activities	-1.000K	-11.00K	2.370M
Cash From Financing Activities	-901.0K	-1.817M	238.9M
Net Change In Cash	-18.23M	21.00M	224.6M
YoY Change	-70.24%	-90.65%	1190.92%
FREE CASH FLOW
Cash From Operating Activities	-$17.32M	$22.83M	-$16.63M
Capital Expenditures	-$1.000K	-$11.00K	-$240.0K
Free Cash Flow	-$17.32M	$22.84M	-$16.39M
YoY Change	35.97%	-239.33%	-47.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38067
	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
	dei	Entity Address City Or Town EntityAddressCityOrTown	London
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
	dei	Entity Address Country EntityAddressCountry	GB
	dei	Country Region CountryRegion	44
	dei	City Area Code CityAreaCode	203
	dei	Local Phone Number LocalPhoneNumber	283 4200
	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
	dei	Trading Symbol TradingSymbol	VRNA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	480082966	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166547000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187986000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6672000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4538000	USD
CY2021Q3	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	10606000	USD
CY2020Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	8260000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	667000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1720000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	184492000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	202504000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	545000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	545000	USD
CY2021Q3	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	0	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1435000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1050000	USD
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	17068000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1702000	USD
CY2021Q3	us-gaap	Assets Assets	201560000	USD
CY2020Q4	us-gaap	Assets Assets	204206000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	178000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26457000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10863000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	690000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	798000	USD
CY2021Q3	vrna	Warrant Liability Current WarrantLiabilityCurrent	2000	USD
CY2020Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	2246000	USD
CY2021Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	397000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	185000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	118000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	27740000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14203000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4821000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4635000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	797000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	514000	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5618000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5149000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	33358000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	19352000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	489177550	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	488304446	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	477649646	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	463304446	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	31855000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	31794000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	382005000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	366411000	USD
CY2021Q3	us-gaap	Treasury Stock Value TreasuryStockValue	770000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1700000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-240287000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-207050000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	168202000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	201560000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204206000	USD
CY2021Q3	us-gaap	Revenues Revenues	40000000	USD
CY2020Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	40000000	USD
	us-gaap	Revenues Revenues	0	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22560000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12820000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56697000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28259000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10883000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8284000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28150000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18318000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	33443000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	21104000	USD
	us-gaap	Operating Expenses OperatingExpenses	84847000	USD
	us-gaap	Operating Expenses OperatingExpenses	46577000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	6557000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21104000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44847000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-46577000	USD
CY2021Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	4749000	USD
CY2020Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	2338000	USD
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	10655000	USD
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	5809000	USD
CY2021Q3	us-gaap	Investment Income Net InvestmentIncomeNet	4000	USD
CY2020Q3	us-gaap	Investment Income Net InvestmentIncomeNet	13000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	11000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	116000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	86000	USD
	us-gaap	Interest Expense InterestExpense	255000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q3	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	40000	USD
CY2020Q3	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	-978000	USD
	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	2244000	USD
	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	-747000	USD
CY2021Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-86000	USD
CY2020Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	844000	USD
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	117000	USD
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	1188000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4621000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2217000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12772000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6366000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11178000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18887000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32075000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40211000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	127000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	232000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	110000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11051000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-18931000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-32307000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40321000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2321000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	11051000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18931000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32307000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42642000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	475334354	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	344809792	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	471159171	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	197049240	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	515819439	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	344809792	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	471159171	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	197049240	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8850000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	172414000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22068000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7450000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3782000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	383000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	154397000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11051000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4938000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2167000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	350000	USD
CY2021Q3	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	367000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	168202000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	42741000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12346000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2157000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1867000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	52000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	30157000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9044000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-164000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	950000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-52000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	21847000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-18931000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6486000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	187360000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	196762000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-32307000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40321000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-556000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1282000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	92000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	94000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2244000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	747000	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	289000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21238000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9303000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	467000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	472000	USD
	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	15000000	USD
	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	0	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2134000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2444000	USD
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	2677000	USD
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-3336000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1053000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1151000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	823000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-169000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-983000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15595000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3916000	USD
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	177000	USD
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-461000	USD
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	451000	USD
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	0	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-300000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-4000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15931000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26281000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	73000	USD
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	USD
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	9792000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9719000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	200156000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11763000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5949000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	733000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5216000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	188393000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-281000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-291000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21439000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	171540000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30428000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166547000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201968000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2021Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.86
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-240300000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	873104	shares
	us-gaap	Interest Paid Net InterestPaidNet	162000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	700000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	subsidiary
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	subsidiary
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the initial recognition of the value of the equity interest and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2021Q3	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	3568000	USD
CY2020Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	2551000	USD
CY2021Q3	us-gaap	Prepaid Insurance PrepaidInsurance	2713000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1701000	USD
CY2021Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	391000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	286000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6672000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4538000	USD
CY2021Q3	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	10606000	USD
CY2020Q4	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	8202000	USD
CY2021Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	58000	USD
CY2021Q3	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	10606000	USD
CY2020Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	8260000	USD
CY2021Q3	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	24063000	USD
CY2020Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	8607000	USD
CY2021Q3	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	995000	USD
CY2020Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2149000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1399000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	107000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26457000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10863000	USD
CY2020	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2021Q3	vrna	Class Of Warrant Or Right Intrinsic Value ClassOfWarrantOrRightIntrinsicValue	0	USD
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y7M6D
CY2020Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y3M18D
CY2021Q3	vrna	Warrant Liability Current WarrantLiabilityCurrent	2000	USD
CY2020Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	2246000	USD
CY2021Q3	vrna	Sensitivity Analysis Of Fair Value Warrant Liability Impact Of10 Percent Increase In Volatility Rate SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate	11000	USD
CY2021Q3	vrna	Warrant Liability Fair Value WarrantLiabilityFairValue	2000	USD
CY2021Q3	vrna	Sensitivity Analysis Of Fair Value Warrant Liability Impact Of10 Percent Decrease In Volatility Rate SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate	0	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4800000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4938000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6486000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21238000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9303000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13125672	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.41
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	996720	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.17
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12128952	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.43
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	800000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.73
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12928952	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	576000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.78
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	638112	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.75
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12866840	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.39
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11051000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-18931000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-32307000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40321000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	475334354	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	344809792	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	471159171	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	197049240	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	515819439	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	344809792	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	471159171	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	197049240	shares
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25139377	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	88402414	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	88402414	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65624462	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	88402414	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	88402414	shares

Files In Submission

Name	View Source	Status
0001657312-21-000037-index-headers.html	Edgar Link	pending
0001657312-21-000037-index.html	Edgar Link	pending
0001657312-21-000037.txt	Edgar Link	pending
0001657312-21-000037-xbrl.zip	Edgar Link	pending
exhibit311q321.htm	Edgar Link	pending
exhibit312q321.htm	Edgar Link	pending
exhibit321q321.htm	Edgar Link	pending
exhibit322q321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20210930.htm	Edgar Link	pending
vrna-20210930.xsd	Edgar Link	pending
vrna-20210930_cal.xml	Edgar Link	unprocessable
vrna-20210930_def.xml	Edgar Link	unprocessable
vrna-20210930_htm.xml	Edgar Link	completed
vrna-20210930_lab.xml	Edgar Link	unprocessable
vrna-20210930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2021 Q4 Form 10-Q Financial Statement

#000165731221000037 Filed on November 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2021 Q4 Form 10-Q Financial Statement

#000165731221000037 Filed on November 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna